Literature DB >> 10720503

Determinants of the quantity of hepatitis C virus RNA.

D L Thomas1, J Astemborski, D Vlahov, S A Strathdee, S C Ray, K E Nelson, N Galai, K R Nolt, O Laeyendecker, J A Todd.   

Abstract

To test the hypothesis that person-to-person variability in blood levels of hepatitis C virus (HCV) RNA can be explained, the quantity of HCV RNA was assessed in 969 persons who acquired HCV infection in the context of injection drug use. Serum HCV RNA levels ranged from 200,000 to >120 million equivalents/mL (the linear range of the assay). The median log10 HCV RNA level was 0.46 higher in 468 human immunodeficiency virus (HIV)-positive persons than in 501 HIV-negative persons (P<.001). In addition, among HIV-negative persons, lower HCV RNA levels were independently associated with younger age (P<.001), ongoing hepatitis B infection (P=.005), and the absence of needle sharing (P=.02). However, >90% of the person-to-person HCV RNA level variability was not explained by these sociodemographic, environmental, and virologic factors. Additional research is necessary to ascertain what determines the level of HCV RNA in blood.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10720503     DOI: 10.1086/315314

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

Review 1.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

2.  Correlates of high hepatitis C virus RNA load in a cohort of HIV-negative and HIV-positive individuals with haemophilia.

Authors:  S M Gadalla; L R Preiss; M E Eyster; J J Goedert
Journal:  J Viral Hepat       Date:  2011-03       Impact factor: 3.728

Review 3.  Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes.

Authors:  Yaron Rotman; T Jake Liang
Journal:  J Virol       Date:  2009-05-06       Impact factor: 5.103

Review 4.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

5.  Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users.

Authors:  Basmattee Boodram; Ronald C Hershow; Scott J Cotler; Lawrence J Ouellet
Journal:  Drug Alcohol Depend       Date:  2011-07-02       Impact factor: 4.492

Review 6.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

7.  Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study.

Authors:  B Hajarizadeh; B Grady; K Page; A Y Kim; B H McGovern; A L Cox; T M Rice; R Sacks-Davis; J Bruneau; M Morris; J Amin; J Schinkel; T Applegate; L Maher; M Hellard; A R Lloyd; M Prins; R B Geskus; G J Dore; J Grebely
Journal:  J Viral Hepat       Date:  2015-01-08       Impact factor: 3.728

8.  Acute hepatitis C virus infection in a nurse trainee following a needlestick injury.

Authors:  Renzo Scaggiante; Liliana Chemello; Roberto Rinaldi; Giovanni Battista Bartolucci; Andrea Trevisan
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

9.  Hepatitis C virus (HCV) core antigen assay to detect ongoing HCV infection in thai injection drug users.

Authors:  Dale M Netski; Xiao-Hong Wang; Shruti H Mehta; Kenrad Nelson; David Celentano; Satawat Thongsawat; Niwat Maneekarn; Vinai Suriyanon; Jaroon Jittiwutikorn; David L Thomas; John R Ticehurst
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

10.  HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study.

Authors:  Gregory D Kirk; Shruti H Mehta; Jacquie Astemborski; Noya Galai; Jonathan Washington; Yvonne Higgins; Ashwin Balagopal; David L Thomas
Journal:  Ann Intern Med       Date:  2013-05-07       Impact factor: 25.391

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.